Because AR-V7 lacks the androgen-receptor ligand-binding domain, AR-V7-positive prostate cancers are generally resistant to novel hormonal therapies including abiraterone and enzalutamide [2, 3]. The gene discussed is AR; the disease is Familial prostate cancer.